Evidence map›Paper›PMID 40990156›Full record

ArticlemAbs2025

A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology.

Shahzada Khan, Jeremy Lum, Heather Stephenson, Pawan Bir Kohli, David Mortenson, Dhivya Ramakrishnan, Magdeleine Hung, Sheng Ding, Elbert Seto, Sabrina Lu and 15 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Shahzada KhanBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Jeremy LumBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Heather StephensonProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Pawan Bir KohliBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
David MortensonStructural Chemistry, Gilead Sciences, Inc., Foster City, CA, USA.
Dhivya RamakrishnanBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Magdeleine Hung
Sheng DingProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Elbert SetoProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Sabrina LuProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Randy YenProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Debi JinProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Brian LeeProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Sheila ClancyBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Nicole Schirle OakdaleProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.ORCID 0000-0003-2965-4262
Nikolai NovikovProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Don KangBioinformatics, Gilead Sciences, Inc., Foster City, CA, USA.
Ruidong LiBioinformatics, Gilead Sciences, Inc., Foster City, CA, USA.
David PanBioinformatics, Gilead Sciences, Inc., Foster City, CA, USA.
Rutwij DaveDrug Metabolism, Gilead Sciences, Inc., Foster City, CA, USA.
Eric LansdonStructural Chemistry, Gilead Sciences, Inc., Foster City, CA, USA.
Simon P FletcherBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Abhishek V GargBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.
Nathan ThomsenProtein Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA.
Scott BalsitisBiology, Gilead Sciences, Gilead Sciences, Inc., Foster City, CA, USA.

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
NIGMS NIH HHS P30 GM124169NIH HHS S10 OD021832
6 · The paper itself

Abstract

Curative therapies for chronic hepatitis B virus infection (CHB) are needed, and T-cell redirection is a promising approach, with peptide-MHC complexes (pMHC) being attractive targets. HBV core

Indexed as

Hepatitis B, ChronicHepatitis B virusHLA-A2 AntigenReceptors, Antigen, T-CellAnimalsCD8-Positive T-LymphocytesHepatocytesHumansMicePeptidesHLA-A*02:01 antigenHLA-A2 AntigenPeptidesReceptors, Antigen, T-CellConservationcore peptidediabodyHBcAgHBVHBV cureHBV genotypepMHC complexT cell engagerTCR-like antibody

Identifiers

PMID40990156
PMCPMC12461897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.